Stem Cell Transplantation for Sickle Cell Anemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01877837 |
Recruitment Status :
Completed
First Posted : June 14, 2013
Results First Posted : November 7, 2022
Last Update Posted : November 7, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sickle Cell Disease | Drug: Alemtuzumab Drug: Fludarabine Drug: Melphalan Procedure: Stem Cells | Phase 3 |
Primary objective:
1) To determine disease free survival (DFS) at two years after matched sibling transplant using bone marrow (BM) after a conditioning regimen consisting of distal timed Alemtuzumab, Fludarabine, and Melphalan for patients 2-30 y/o
Secondary objectives:
- Overall survival
- Rate of neutrophil and platelet engraftment for BM
- Incidence of graft failure
- Incidence of grade II-IV and grade III-IV acute graft vs host disease (GVHD)
- Incidence of chronic GVHD
- Incidence of other transplant complications, such as veno-occlusive disease, central nervous system (CNS) toxicity, and idiopathic pneumonia syndrome (IPS)
- Incidence of reactivation of CMV, EBV, adenovirus, BK/JC virus
- Incidence of invasive fungal disease
- Time to immune reconstitution via monitoring of lymphocyte subpopulations and immunoglobulin levels
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Reduced Intensity Matched Sibling Bone Marrow Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old |
Study Start Date : | June 2011 |
Actual Primary Completion Date : | September 2021 |
Actual Study Completion Date : | September 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Related donor
Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan. 1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below. Day Treatment
|
Drug: Alemtuzumab
Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)] b) Medications i.) Alemtuzumab I. Hb S% must be < or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below Other Name: Alemtuzumab (Campath) Drug: Fludarabine I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
Other Name: Fludarabine (Fludara) Drug: Melphalan I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion. Other Name: Melphalan (Alkeran) Procedure: Stem Cells Infusion of Hematopoietic Stem Cells |
- Number of Participants With Graft Failure [ Time Frame: 2 years ]
Primary endpoint:
In each group, the Number of participants with Graft Failure at the 2 years endpoint will be estimated using the Kaplan Meier product limit estimator.
- Overall Survival [ Time Frame: 2 years ]
Secondary endpoints:
Overall survival: The distribution of time to death from any cause will be estimated by Kaplan- Meier product limit function and plotted. The overall survival will be measured from the time of transplant to any death and patients will be followed for 2 years.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 30 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patient Eligibility
1) Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single or double) with a total TNC dose of greater than 5 x 107/kg recipient weight)
- Age 2-30
- Hb SS, S-thal0, S-thal+, SC
- Evidence of ongoing hemolysis: Hb<10, retic >5%, LDH > 500, TB>2
- Karnofsky/Lansky score >50
- LVSF>26% or LVEF>40%
- DLCO >40% or O2 sat >85% for those patients that can't perform PFTs
- GFR >70 and serum creatinine < 1.5 * ULN for age
- ALT and AST < 5 x ULN, direct bilirubin <2 x ULN
- If the patient has been on chronic transfusion or has a ferritin >1000, liver biopsy should be done and show no evidence of bridging fibrosis or cirrhosis
-
Exclusion criteria
- Evidence of uncontrolled bacterial, viral, or fungal infection within one month prior to initiation of the conditioning regimen
- Pregnant or breastfeeding
- HIV positive
- Written informed consent not obtained

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01877837
United States, New Jersey | |
Hackensack University Medical Center | |
Hackensack, New Jersey, United States, 07601 |
Principal Investigator: | Jennifer Krajewski, MD | Hackensack Meridian Health |
Documents provided by Hackensack Meridian Health:
Responsible Party: | Hackensack Meridian Health |
ClinicalTrials.gov Identifier: | NCT01877837 |
Other Study ID Numbers: |
Pro00001894 |
First Posted: | June 14, 2013 Key Record Dates |
Results First Posted: | November 7, 2022 |
Last Update Posted: | November 7, 2022 |
Last Verified: | October 2022 |
Stem cell transplant Sickle cell Stem cell transplantation Related Unrelated |
Anemia, Sickle Cell Anemia Hematologic Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Fludarabine Fludarabine phosphate Melphalan Alemtuzumab |
Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Alkylating Alkylating Agents Myeloablative Agonists Antineoplastic Agents, Immunological |